Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1306.69 +35.94 (2.83%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1270.75 | 52 Week High | $88.16 | |||
| Open | $1281.76 | 52 Week Low | $67.88 | |||
| Day High | $1321.21 | P/E | 302.47 | |||
| Day Low | $1275.10 | EPS | $4.32 | |||
| Volume | 2,659,785 | |||||
